Global Information
회사소개 | 문의 | 비교리스트

만성 골수성 백혈병(CML) : 역학 예측(-2030년)

Chronic Myeloid Leukemia (CML) - Epidemiology Forecast to 2030

리서치사 GlobalData
발행일 2021년 12월 상품코드 1054013
페이지 정보 영문 37 Pages 배송안내
가격
US $ 3,995 ₩ 5,142,000 PDF (Single User License) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 7,990 ₩ 10,285,000 PDF (Site License) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 11,985 ₩ 15,428,000 PDF (Global License) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


만성 골수성 백혈병(CML) : 역학 예측(-2030년) Chronic Myeloid Leukemia (CML) - Epidemiology Forecast to 2030
발행일 : 2021년 12월 페이지 정보 : 영문 37 Pages

본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

만성 골수성 백혈병(CML) 주요 8개 시장(8MM : 미국, 프랑스, 독일, 이탈리아, 스페인, 영국, 일본, 캐나다)의 진단된 인시던트 케이스는 2020년에 1만 5,515건이 되고, 2030년에는 1만 7,562건이 될 것으로 예측됩니다. 또한 예측기간 중 AGR은 1.32%입니다.

8MM의 만성 골수성 백혈병(CML) 시장을 조사했으며, CML의 위험인자, 병존질환, COVID-19의 영향, 세계 및 과거의 역학적 동향에 대해 설명하고 있습니다.

목차

목차

제1장 만성 골수성 백혈병 : 주요 요약

  • 촉매
  • 관련 보고서
  • 향후 보고서

제2장 역학

  • 질병 배경
  • 위험인자와 병존질환
  • 세계적 및 역사적 동향
  • 8MM 예측 조사 방법
    • 소스
    • 예측 가정과 방법
    • CML 진단된 인시던트 케이스
    • 병기 분류별 CML 진단된 인시던트 케이스
    • 위험 상황별 CML 진단된 인시던트 케이스
    • T315I 변이별 CML 진단된 인시던트 케이스
    • CML 5년, 10년, 15년, 20년 진단된 유병률
  • CML 역학 예측(2020-2030)
    • CML 진단된 인시던트 케이스
    • CML 연령별 진단된 인시던트 케이스
    • CML 성별 진단된 인시던트 케이스
    • 병기 분류별 CML 진단된 인시던트 케이스
    • 위험 상황별 CML 진단된 인시던트 케이스
    • T315I 변이별 CML 진단된 인시던트 케이스
    • 20년간 진단된 CML 유병률
  • 논의
    • 역학 예측 인사이트
    • COVID-19의 영향
    • 분석의 한계
    • 분석의 강점

제3장 부록

  • 참고문헌
  • 저자 소개
    • 역학자
    • 리뷰어
    • 치료 분석 및 역학의 세계 디렉터
    • 헬스케어 사업 및 전략의 세계 헤드 및 EVP
  • 문의
KSM 22.03.10

List of Tables

List of Tables

  • Table 1: Summary of Newly Added Data Types
  • Table 2: Summary of Updated Data Types
  • Table 3: Risk Factors and Comorbid Conditions Associated with CML

List of Figures

List of Figures

  • Figure 1: 8MM, Diagnosed Incident Cases of CML, Both Sexes, N, All Ages, 2020 and 2030
  • Figure 2: 8MM, 20-Year Diagnosed Prevalent Cases of CML, Both Sexes, N, All Ages, 2020 and 2030
  • Figure 3: 8MM, Diagnosed Incidence of CML, Men, Cases Per 100,000 Population, All Ages, 2010-2030
  • Figure 4: 8MM, Diagnosed Incidence of CML, Women, Cases Per 100,000 Population, All Ages, 2010-2030
  • Figure 5: 8MM, Sources Used to Forecast Diagnosed Incident Cases of CML (ICD-10 = C92.1)
  • Figure 6: 8MM, Sources Used to Forecast the Five-, 10-, 15-, and 20-Year Diagnosed Prevalent Cases of CML (ICD-10 = C92.1)
  • Figure 7: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of CML (ICD-10 = C92.1) by Staging
  • Figure 8: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of CML (ICD-10 = C92.1) by Risk Status
  • Figure 9: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of CML (ICD-10 = C92.1) by T315I Mutation
  • Figure 10: 8MM, Diagnosed Incident Cases of CML, N, Both Sexes, All Ages, 2020
  • Figure 11: 8MM, Diagnosed Incident Cases of CML by Age, N, All Ages, 2020
  • Figure 12: 8MM, Diagnosed Incident Cases of CML by Sex, N, All Ages, 2020
  • Figure 13: 8MM, Diagnosed Prevalent Cases of CML by Staging, N, All Ages, 2020
  • Figure 14: 8MM, Diagnosed Incident Cases of CML by Risk Status, N, All Ages, 2020
  • Figure 15: 8MM, Diagnosed Incident Cases of CML by T315I Mutation, N, Both Sexes, All Ages, 2020
  • Figure 16: 8MM, 20-Year Diagnosed Prevalent Cases of CML, N, Both Sexes, All Ages, 2020

Chronic myeloid leukemia (CML) (ICD-10 = C92.1) is a rare cancer of the white blood cells characterized by increased and unregulated growth of myeloid cells originating in the bone marrow that invade the blood and potentially other organs, depending on the phase of the cancer (American Cancer Society, 2018; Mayo Clinic, 2021). In CML, a genetic change takes place in an early (immature) version of myeloid cells, the cells that make red blood cells, platelets, and most types of white blood cells (except lymphocytes). Based on clinical characteristics and laboratory findings, CML is divided into three phases: chronic, accelerated, and blast crisis; most people with CML are diagnosed at the chronic phase (American Cancer Society, 2018).

This report provides an overview of the risk factors, comorbidities, and the global and historical epidemiological trends for CML in the eight major markets (8MM: US, France, Germany, Italy, Spain, UK, Japan, and Canada). The report includes a 10-year epidemiology forecast for the diagnosed incident cases of CML. The diagnosed incident cases are segmented by age (all ages), sex, staging (chronic phase, accelerated phase, and blast phase), risk status (low-risk, intermediate-risk, and high-risk), and T315I mutation. The report also provides a 10-year epidemiological forecast of the 20-year diagnosed prevalent cases of CML. The following data describes epidemiology of CML. In the 8MM, GlobalData epidemiologists forecast an increase in the diagnosed incident cases of CML from 15,515 diagnosed incident cases of CML in 2020 to 17,562 diagnosed incident cases of CML in 2030, with an AGR of 1.32% during the forecast period. The 20-year diagnosed prevalent cases of CML in the 8MM are expected to increase from 142,404 cases in 2020 to 170,488 cases in 2030, with an AGR of 1.97% during the forecast period. Men accounted for more diagnosed incident cases of CML than women in the 8MM and it predominantly affects older adults. These findings are in line with the GlobalData estimates and these trends are reflected in GlobalData's forecast for the diagnosed incident cases for the 8MM.

Scope

  • The Chronic Myeloid Leukemia (CML) Epidemiology Report provides an overview of the risk factors and global trends of CML in the eight major markets (8MM: US, France, Germany, Italy, Spain, UK, Japan, and Canada).
  • The report includes a 10-year epidemiological forecast for the diagnosed incident cases of CML. The diagnosed incident cases are segmented by age (all ages), sex, staging (chronic phase, accelerated phase, and blast phase), risk status (low-risk, intermediate-risk, and high-risk), and T315I mutation. The report also provides a 10-year epidemiological forecast of the 20-year diagnosed prevalent cases of CML. The model associated with this report additionally provides diagnosed incident cases of CML segmented by blast phase-lymphoid and blast phase-myeloid leukemia, as well as five-, 10-, and 15-year diagnosed prevalent cases of CML.
  • The CML epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 8MM.

Reasons to Buy

The Chronic Myeloid Leukemia (CML) Epidemiology series will allow you to -

  • Develop business strategies by understanding the trends shaping and driving the global CML market.
  • Quantify patient populations in the global CML market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for CML therapeutics in each of the markets covered.
  • Understand magnitude of CML population by subtype, digital vasculopathy, and other internal organ involvement.

Table of Contents

Table of Contents

1 Chronic Myeloid Leukemia: Executive Summary

  • 1.1 Catalyst
  • 1.2 Related Reports
  • 1.3 Upcoming Reports

2 Epidemiology

  • 2.1 Disease Background
  • 2.2 Risk Factors and Comorbidities
  • 2.3 Global and Historical Trends
  • 2.4 8MM Forecast Methodology
    • 2.4.1 Sources
    • 2.4.2 Forecast Assumptions and Methods
    • 2.4.3 Diagnosed Incident Cases of CML
    • 2.4.4 Diagnosed Incident Cases of CML by Staging
    • 2.4.5 Diagnosed Incident Cases of CML by Risk Status
    • 2.4.6 Diagnosed Incident Cases of CML by T315I Mutation
    • 2.4.7 Five-, 10-, 15-, 20-Year Diagnosed Prevalent Cases of CML
  • 2.5 Epidemiological Forecast for CML (2020-2030)
    • 2.5.1 Diagnosed Incident Cases of CML
    • 2.5.2 Age-Specific Diagnosed Incident Cases of CML
    • 2.5.3 Sex-Specific Diagnosed Incident Cases of CML
    • 2.5.4 Diagnosed Incident Cases of CML by Staging
    • 2.5.5 Diagnosed Incident Cases of CML by Risk Status
    • 2.5.6 Diagnosed Incident Cases of CML by T315I Mutation
    • 2.5.7 20-Year Diagnosed Prevalent Cases of CML
  • 2.6 Discussion
    • 2.6.1 Epidemiological Forecast Insight
    • 2.6.2 COVID-19 Impact
    • 2.6.3 Limitations of the Analysis
    • 2.6.4 Strengths of the Analysis

3 Appendix

  • 3.1 Bibliography
  • 3.2 About the Authors
    • 3.2.1 Epidemiologist
    • 3.2.2 Reviewers
    • 3.2.3 Global Director of Therapy Analysis and Epidemiology
    • 3.2.4 Global Head and EVP of Healthcare Operations and Strategy
  • Contact Us
Back to Top
전화 문의
F A Q